Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD30-positive Solid Tumor”

2 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 2 of 2 results

Early research (Phase 1)WithdrawnNCT02780011
What this trial is testing

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

Who this might be right for
CD30-positive LymphomaCD30-positive Solid Tumor
Eric Bernicker, MD
Testing effectiveness (Phase 2)Study completedNCT01461538
What this trial is testing

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Who this might be right for
Acute Lymphoid LeukemiaAcute Myeloid LeukemiaAnemia, Refractory, With Excess of Blasts+1 more
Seagen Inc. 84